MISTMilestone Pharmaceuticals Inc.Healthcare · Biotechnologyas of 2026-09-18
Horizon

Issued 2026-09-18 at $1.05 · now $0.79 (2026-09-25, −24.9% since)

Based on its own history, a month from the 2026-09-18 close, MIST has typically landed between $0.74 and $1.41 — a range of −29.4% to +33.9% from the issuance price $1.05.

Range of outcomes in historically similar periods — not a price prediction. Ranges are scored publicly on /methodology.
  • Actual close
  • Typical path (median)
  • Middle 50% of outcomes
  • 90% range

1,827 overlapping 1 month windows · 2019-05-09 – 2026-08-19 · basis climatology · forecast (batch). Base rate up 53.9% (90% CI 51.7–56.1%, ≈1,413 obs). Not a call on this stock — we have no evidence its odds differ.

The cone is anchored at the 2026-09-18 issuance close ($1.05) — the price the forecast resolves against on 2026-10-19, not the latest close. The drawn path shape is illustrative (bands widen with √t); every labeled number is real — the anchor, the scored batch p90/IQR endpoints, and the typical move.

Where MIST has typically landed a month from the 2026-09-18 close of $1.05 — the range is history, not a prediction.

$0.7412worst · -29.4%$1.41best · +33.9%
  • now $0.7884 (-24.9%)
  • typicalThe typical outcome — half of similar past periods did better and half did worse (not an average, so a few wild periods don't skew it). $1.04 (-1.4%)
  • middle 50%The central range of outcomes — half of similar past periods landed inside it, a quarter finished above, a quarter below. $0.9155–$1.16
  • 90% rangeA nine-in-ten range — in about nine of every ten similar past periods the outcome stayed within these bounds. $0.7412–$1.41
Actual 1-month windows behind the coneiEvery overlapping 1-month window in this security's own price history was ranked by realized return; shown are the 3 worst and 3 best of 1,832 windows spanning 2019-05-09 to 2026-09-25. Not cherry-picked — these are the extremes of the full sample. Max drop / max rise are the deepest and highest points reached within each window. See /methodology.
StartReturnMax dropMax rise
3 worst
2020-03-06−90.7%−91.4%+0.0%
2020-02-24−90.5%−90.5%+0.0%
2020-02-27−90.5%−90.5%+4.6%
3 best
2020-07-14+161.7%+0.0%+193.4%
2020-07-16+159.6%−2.9%+184.9%
2020-07-20+152.8%−0.3%+192.5%

1,832 overlapping windows · 2019-05-09 – 2026-09-25 · not cherry-picked

Pending catalysts

  • 2027-06-01 — Trial primary completion: Phase 2 primary completion: The NODE-202 Study (Study of Etripamil Nasal Spray in Pediatric Patients) (source, as of 2026-08-14)

Public, scheduled events — dated attention, not a prediction of the outcome. See the FDA catalysts page for the historical base rate.

Seasonality · by month iHow this security has tended to do in each calendar month historically — a frequency, never a prediction.

iFor each calendar month, the share of years this security closed higher than the month before, and the average month-over-month return, over ~8 years of its own price history. Cells are shaded by average return. This is historical frequency, not a prediction — no month is a signal.
Jan
43%
+2.9%
n=7
Feb
14%
−11.6%
n=7
Mar
43%
−18.6%
n=7
Apr
71%
+24.1%
n=7
May
57%
−0.9%
n=7
Jun
50%
+3.2%
n=8
Jul
63%
+11.8%
n=8
Aug
63%
+8.0%
n=8
Sep
50%
−2.9%
n=8
Oct
14%
−13.1%
n=7
Nov
57%
+15.3%
n=7
Dec
29%
−8.7%
n=7

Up-frequency and average month-over-month return · historical frequency, not a prediction

Reported insider & political trades

Every Form 4 the people closest to this company have filed with the SEC — plotted against the share price, aggregated by month, and shown with the gap between when each trade happened and when it was disclosed. A public record, not advice.

Share price & reported tradesMonthly open-market valueReporting lag — trade date to filing date2026-092026-082026-072026-062026-052026-042026-032026-022026-012025-122025-112025-102025-092025-08$3$12026-04-16: 1 insider sale, $82K — Oliveto Joseph2026-01-26: 5 insider sales, $159K — Oliveto Joseph, Bharucha David, Nelson Jeffrey Edward, Hasija Amit …2026-01-08: 1 insider sale, $97K — Oliveto Joseph2026-01-07: 1 insider sale, $1K — Oliveto Joseph2025-12-15: 5 insider sales, $837K — Oliveto Joseph, Hasija Amit, Bharucha David, Nelson Jeffrey Edward …2025-12: 5 open-market sales, $837K2026-01: 7 open-market sales, $257K2026-04: 1 open-market sale, $82K↑ buys↓ salesdirector Oliveto Joseph — Sale on 2026-04-16, filed 4 days after the tradedirector Oliveto Joseph — Sale on 2026-01-26, filed 2 days after the tradeofficer Bharucha David — Sale on 2026-01-26, filed 2 days after the tradeofficer Nelson Jeffrey Edward — Sale on 2026-01-26, filed 2 days after the tradeofficer Hasija Amit — Sale on 2026-01-26, filed 2 days after the tradeofficer Muller Lorenz — Sale on 2026-01-26, filed 2 days after the tradedirector Oliveto Joseph — Sale on 2026-01-08, filed 1 day after the tradedirector Oliveto Joseph — Sale on 2026-01-07, filed 2 days after the tradedirector Oliveto Joseph — Sale on 2025-12-15, filed 44 days after the tradeofficer Hasija Amit — Sale on 2025-12-15, filed 44 days after the tradeofficer Bharucha David — Sale on 2025-12-15, filed 44 days after the tradeofficer Nelson Jeffrey Edward — Sale on 2025-12-15, filed 44 days after the tradeofficer Muller Lorenz — Sale on 2025-12-15, filed 44 days after the trade
DatePersonRoleActionShares @ priceValueOwnership Δvs S&P 1mvs S&P 6mOwned afterFiling
2026-04-16Oliveto JosephdirectorSale36,500 @ $2.26$82K−7.6% of holding−33.1%not yet — horizon still open446,244Form 4 · filed 4 days after the trade
2026-01-26Oliveto JosephdirectorSale34,523 @ $1.93$67K−6.7% of holding−10.9%−52.4%482,744Form 4 · filed 2 days after the trade
2026-01-26Bharucha DavidofficerSale12,245 @ $1.93$24K−9.8% of holding−10.9%−52.4%113,181Form 4 · filed 2 days after the trade
2026-01-26Nelson Jeffrey EdwardofficerSale12,245 @ $1.93$24K−19.7% of holding−10.9%−52.4%49,848Form 4 · filed 2 days after the trade
2026-01-26Hasija AmitofficerSale12,245 @ $1.93$24K−10.9% of holding−10.9%−52.4%99,848Form 4 · filed 2 days after the trade
2026-01-26Muller LorenzofficerSale11,180 @ $1.93$22K−5.2% of holding−10.9%−52.4%205,406Form 4 · filed 2 days after the trade
2026-01-08Oliveto JosephdirectorSale43,000 @ $2.25$97K−12.4% of holding−17.5%−50.8%303,721Form 4 · filed 1 day after the trade
2026-01-07Oliveto JosephdirectorSale500 @ $2.25$1K−0.1% of holding−18.3%−50.5%346,721Form 4 · filed 2 days after the trade
2025-12-15Oliveto JosephdirectorSale133,054 @ $2.32$309K−22.8% of holding−15.6%−53.7%450,667Form 4 · filed 44 days after the trade
2025-12-15Hasija AmitofficerSale58,007 @ $2.32$135K−38.7% of holding−15.6%−53.7%91,993Form 4 · filed 44 days after the trade
2025-12-15Bharucha DavidofficerSale58,007 @ $2.32$135K−35.5% of holding−15.6%−53.7%105,326Form 4 · filed 44 days after the trade
2025-12-15Nelson Jeffrey EdwardofficerSale58,007 @ $2.32$135K−58.0% of holding−15.6%−53.7%41,993Form 4 · filed 44 days after the trade
2025-12-15Muller LorenzofficerSale53,566 @ $2.32$124K−21.4% of holding−15.6%−53.7%196,486Form 4 · filed 44 days after the trade

The vs-S&P columns are a labeled look-back on what the stock did after each filing, measured against the index over the same window. Descriptive history, not a claim about the person or a reason to trade.

116 award / exercise / gift records — not counted as purchases

Awards, option exercises, gifts and tax-withholding disposals are shown separately and never counted as open-market purchases or sales — they carry no conviction information.

DatePersonRoleActionSharesOwned afterFiling
2026-06-10Fischer Seth H. Z.directorAward / grant77,00077,000Form 4
2026-06-10Duty StuartdirectorAward / grant77,00077,000Form 4
2026-06-10Giles Lisa M.directorAward / grant77,00077,000Form 4
2026-06-10TOMSICEK MICHAEL JOHNdirectorAward / grant77,00077,000Form 4
2026-06-10Saik AndrewdirectorAward / grant77,00077,000Form 4
2026-06-10Wills Robert JamesdirectorAward / grant77,00077,000Form 4
2026-06-10PAPA JOSEPH CdirectorAward / grant77,00077,000Form 4
2026-02-02Hasija AmitofficerAward / grant204,000204,000Form 4
2026-02-02Nelson Jeffrey EdwardofficerAward / grant204,000204,000Form 4
2026-02-02Nelson Jeffrey EdwardofficerAward / grant136,000136,000Form 4
2026-02-02Oliveto JosephdirectorAward / grant453,000453,000Form 4
2026-02-02Oliveto JosephdirectorAward / grant679,000679,000Form 4
2026-02-02Bharucha DavidofficerAward / grant136,000136,000Form 4
2026-02-02Bharucha DavidofficerAward / grant204,000204,000Form 4
2026-02-02Muller LorenzofficerAward / grant136,000136,000Form 4
2026-02-02Muller LorenzofficerAward / grant204,000204,000Form 4
2026-02-02Hasija AmitofficerAward / grant136,000136,000Form 4
2026-01-26Nelson Jeffrey EdwardofficerOption exercise20,10060,300Form 4
2026-01-26Hasija AmitofficerOption exercise20,10060,300Form 4
2026-01-26Oliveto JosephdirectorOption exercise66,600199,800Form 4
2026-01-26Bharucha DavidofficerOption exercise20,10060,300Form 4
2026-01-26Muller LorenzofficerOption exercise20,10060,300Form 4
2026-01-26Bharucha DavidofficerOption exercise20,100125,426Form 4
2026-01-26Muller LorenzofficerOption exercise20,100216,586Form 4
2026-01-26Hasija AmitofficerOption exercise20,100112,093Form 4
2026-01-26Nelson Jeffrey EdwardofficerOption exercise20,10062,093Form 4
2026-01-26Oliveto JosephdirectorOption exercise66,600517,267Form 4
2026-01-26Muller LorenzofficerOption exercise20,100216,586Form 4
2026-01-26Bharucha DavidofficerOption exercise20,100125,426Form 4
2026-01-26Nelson Jeffrey EdwardofficerOption exercise20,10062,093Form 4
2026-01-26Oliveto JosephdirectorOption exercise66,600517,267Form 4
2026-01-26Hasija AmitofficerOption exercise20,100112,093Form 4
2025-12-12Oliveto JosephdirectorAward / grant280,000280,000Form 4
2025-12-12Nelson Jeffrey EdwardofficerAward / grant100,000100,000Form 4
2025-12-12Muller LorenzofficerAward / grant100,000100,000Form 4
2025-12-12Bharucha DavidofficerAward / grant100,000100,000Form 4
2025-12-12Hasija AmitofficerAward / grant100,000100,000Form 4
2025-12-12Oliveto JosephdirectorAward / grant280,000583,721Form 4
2025-12-12Bharucha DavidofficerAward / grant100,000163,333Form 4
2025-12-12Muller LorenzofficerAward / grant100,000250,052Form 4

Source: SEC Form 4 filings. Each row links to its original filing.

Across 2012–2021, stocks where a CEO, C-suite officer, or director had recently made an open-market common-stock purchase ran about +28 bp per month above the universe average (n=34,268 stock-weeks). A historical tendency, not a prediction.

Congressional disclosures

No congressional trades disclosed for this company.

Research tool, not investment advice — historical frequencies, not recommendations. A product of Marovel Technologies LLC. Full terms.